Carl H. June

1.4k total papers · 142.9k total citations
656 papers, 85.2k citations indexed

About

Carl H. June is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Carl H. June has authored 656 papers receiving a total of 85.2k indexed citations (citations by other indexed papers that have themselves been cited), including 409 papers in Oncology, 337 papers in Immunology and 176 papers in Molecular Biology. Recurrent topics in Carl H. June's work include CAR-T cell therapy research (379 papers), Immune Cell Function and Interaction (217 papers) and T-cell and B-cell Immunology (143 papers). Carl H. June is often cited by papers focused on CAR-T cell therapy research (379 papers), Immune Cell Function and Interaction (217 papers) and T-cell and B-cell Immunology (143 papers). Carl H. June collaborates with scholars based in United States, Switzerland and United Kingdom. Carl H. June's co-authors include Bruce L. Levine, David L. Porter, Michael Kalos, James L. Riley, Stephan A. Grupp, Craig B. Thompson, Michael C. Milone, David C. Fajgenbaum, Adam Bagg and Michel Sadelain and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Carl H. June

642 papers receiving 83.5k citations

Hit Papers

Chimeric Antigen Receptor... 1989 2026 2001 2013 2014 2011 2013 2018 2020 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    2014 3.9k citations Shannon L. Maude, Noelle V. Frey et al. New England Journal of Medicine profile →
  2. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
    2011 2.7k citations David L. Porter, Bruce L. Levine et al. New England Journal of Medicine profile →
  3. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
    2013 2.6k citations Stephan A. Grupp, Michael Kalos et al. New England Journal of Medicine profile →
  4. CAR T cell immunotherapy for human cancer
    2018 2.1k citations Carl H. June, Roddy S. O’Connor et al. Science profile →
  5. Cytokine Storm
    2020 2.0k citations Carl H. June et al. New England Journal of Medicine profile →
  6. Delivery technologies for cancer immunotherapy
    2019 2.0k citations Rachel Riley, Carl H. June et al. Nature Reviews Drug Discovery profile →
  7. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
    2011 1.8k citations Michael Kalos, Bruce L. Levine et al. Science Translational Medicine profile →
  8. Chimeric Antigen Receptor Therapy
    2018 1.5k citations Carl H. June, Michel Sadelain New England Journal of Medicine profile →
  9. A human memory T cell subset with stem cell–like properties
    2011 1.4k citations Luca Gattinoni, Enrico Lugli et al. Nature Medicine profile →
  10. Cytokine release syndrome in severe COVID-19
    2020 1.3k citations John B. Moore, Carl H. June Science profile →
  11. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
    2015 1.3k citations David Porter, Wei‐Ting Hwang et al. Science Translational Medicine profile →
  12. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
    2017 1.3k citations Stephen J. Schuster, Jakub Svoboda et al. New England Journal of Medicine profile →
  13. The B7 and CD28 receptor families
    1994 1.1k citations Carl H. June, Jeffrey A. Bluestone et al. Immunology Today profile →
  14. The CD28 Signaling Pathway Regulates Glucose Metabolism
    2002 1.1k citations Kenneth A. Frauwirth, James L. Riley et al. Immunity profile →
  15. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
    2014 971 citations Pablo Tebas, David Stein et al. New England Journal of Medicine profile →
  16. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation
    2004 925 citations Richard V. Parry, Kim E. Nichols et al. The Journal of Immunology profile →
  17. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    2001 913 citations E.Y. Woo, Christina Chu et al. PubMed profile →
  18. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
    2009 889 citations Michael C. Milone, Jonathan D. Fish et al. Molecular Therapy profile →
  19. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
    2016 879 citations Omkar U. Kawalekar, Roddy S. O’Connor et al. Immunity profile →
  20. Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
    1989 815 citations Carl H. June, Jeffrey A. Ledbetter et al. Science profile →
  21. Engineered T cells: the promise and challenges of cancer immunotherapy
    2016 809 citations Andrew D. Fesnak, Carl H. June et al. Nature reviews. Cancer profile →
  22. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    2010 802 citations Claudio G. Brunstein, Jeffrey S. Miller et al. Blood profile →
  23. The Principles of Engineering Immune Cells to Treat Cancer
    2017 776 citations Wendell A. Lim, Carl H. June Cell profile →
  24. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
    2016 732 citations Jiangtao Ren, Xiaojun Liu et al. Clinical Cancer Research profile →
  25. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    2009 689 citations Carmine Carpenito, Michael C. Milone et al. Proceedings of the National Academy of Sciences profile →
  26. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
    2013 688 citations Gregory L. Beatty, Andrew R. Haas et al. Cancer Immunology Research profile →
  27. Role of the CD28 receptor in T-cell activation
    1990 579 citations Carl H. June, Jeffrey A. Ledbetter et al. Immunology Today profile →
  28. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.
    1989 566 citations Craig B. Thompson, Tullia Lindsten et al. Proceedings of the National Academy of Sciences profile →
  29. Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation
    2002 550 citations Edward Y. Woo, Heidi Yeh et al. The Journal of Immunology profile →
  30. Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
    2013 510 citations Albert Lo, John Scholler et al. Cancer Immunology Research profile →
  31. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
    2012 502 citations John Scholler, Gwendolyn Binder-Scholl et al. Science Translational Medicine profile →
  32. Antibody-modified T cells: CARs take the front seat for hematologic malignancies
    2014 490 citations Marcela V. Maus, Stephan A. Grupp et al. Blood profile →
  33. T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
    2013 474 citations Marcela V. Maus, Andrew R. Haas et al. Cancer Immunology Research profile →
  34. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
    2018 472 citations Christopher C. Kloss, Ji‐Hyun Lee et al. Molecular Therapy profile →
  35. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
    2020 445 citations Margaret M. Billingsley, Nathan Singh et al. Nano Letters profile →
  36. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
    2015 432 citations Alfred L. Garfall, Marcela V. Maus et al. New England Journal of Medicine profile →
  37. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
    2018 426 citations Sònia Guedan, Avery D. Posey et al. JCI Insight profile →
  38. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
    2015 425 citations Xiaojun Liu, Shuguang Jiang et al. Cancer Research profile →
  39. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
    2016 416 citations Xiaojun Liu, Shuguang Jiang et al. Cancer Research profile →
  40. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
    2015 404 citations Albert Lo, John Scholler et al. Cancer Research profile →
  41. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
    2017 391 citations Biliang Hu, Jiangtao Ren et al. Cell Reports profile →
  42. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
    2018 371 citations Gregory L. Beatty, Mark H. O’Hara et al. Gastroenterology profile →
  43. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
    2016 340 citations Scott L. Weiss, Shannon L. Maude et al. profile →
  44. Ibrutinib treatment improves T cell number and function in CLL patients
    2017 284 citations Meixiao Long, Kyle A. Beckwith et al. Journal of Clinical Investigation profile →
  45. CAR T therapy beyond cancer: the evolution of a living drug
    2023 267 citations Daniel Baker, Zoltàn Arany et al. Nature profile →
  46. Nanomaterials for T-cell cancer immunotherapy
    2021 246 citations Ningqiang Gong, Neil C. Sheppard et al. Nature Nanotechnology profile →
  47. Engineered cellular immunotherapies in cancer and beyond
    2022 190 citations Amanda Finck, Tatiana Blanchard et al. Nature Medicine profile →
  48. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
    2024 130 citations Bruce L. Levine, Marcelo C. Pasquini et al. Nature Medicine profile →
  49. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
    2023 121 citations Zebin Xiao, Leslie Todd et al. Nature Communications profile →
  50. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
    2023 99 citations Sangya Agarwal, M. Ángela Aznar et al. Immunity profile →
  51. Advancements and challenges in CAR T cell therapy in autoimmune diseases
    2024 74 citations Georg Schett, Fabian Müller et al. Nature Reviews Rheumatology profile →
  52. Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
    2023 63 citations Alex G. Hamilton, Kelsey L. Swingle et al. profile →
  53. Beyond the blood: expanding CAR T cell therapy to solid tumors
    2024 51 citations Uğur Uslu, Carl H. June Nature Biotechnology profile →
  54. From concept to cure: The evolution of CAR-T cell therapy
    2025 19 citations Carl H. June et al. Molecular Therapy profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Carl H. June 51.9k 40.6k 24.3k 16.3k 13.9k 656 85.2k
Steven A. Rosenberg 90.0k 1.7× 88.5k 2.2× 37.9k 1.6× 21.1k 1.3× 9.3k 0.7× 962 141.1k
Nicholas P. Restifo 38.9k 0.7× 45.8k 1.1× 17.6k 0.7× 9.7k 0.6× 5.0k 0.4× 346 64.7k
Michel Sadelain 22.8k 0.4× 11.0k 0.3× 16.1k 0.7× 10.6k 0.7× 7.9k 0.6× 361 38.1k
Mark J. Smyth 37.4k 0.7× 52.8k 1.3× 20.1k 0.8× 3.6k 0.2× 3.3k 0.2× 595 81.3k
Ira Pastan 30.0k 0.6× 20.3k 0.5× 45.5k 1.9× 10.2k 0.6× 2.1k 0.1× 1.2k 89.9k
Drew M. Pardoll 44.9k 0.9× 46.7k 1.1× 23.4k 1.0× 6.0k 0.4× 3.6k 0.3× 404 82.9k
Laurence Zitvogel 31.2k 0.6× 42.2k 1.0× 31.5k 1.3× 4.0k 0.2× 7.4k 0.5× 491 78.6k
Erkki Ruoslahti 11.0k 0.2× 9.2k 0.2× 43.9k 1.8× 5.5k 0.3× 12.2k 0.9× 467 91.3k
Gordon J. Freeman 38.4k 0.7× 54.0k 1.3× 14.7k 0.6× 4.1k 0.3× 1.8k 0.1× 419 82.2k
Zena Werb 35.3k 0.7× 18.4k 0.5× 45.5k 1.9× 7.9k 0.5× 7.3k 0.5× 416 110.0k

Countries citing papers authored by Carl H. June

Since Specialization
Citations

This map shows the geographic impact of Carl H. June's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl H. June with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl H. June more than expected).

Fields of papers citing papers by Carl H. June

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl H. June. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl H. June. The network helps show where Carl H. June may publish in the future.

Co-authorship network of co-authors of Carl H. June

This figure shows the co-authorship network connecting the top 25 collaborators of Carl H. June. A scholar is included among the top collaborators of Carl H. June based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl H. June. Carl H. June is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John H. Krystal Breakdown of academic impact, for papers by Nico van Rooijen Breakdown of academic impact, for papers by Martin Karplus Breakdown of academic impact, for papers by Tony Hunter Breakdown of academic impact, for papers by Robert J. Glynn Breakdown of academic impact, for papers by F. Stuart Chapin Breakdown of academic impact, for papers by Qiang Xü Breakdown of academic impact, for papers by Vincent M. Rotello
Rankless by CCL
2026